Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk

This study has been completed.
Sponsor:
Information provided by:
IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT00520962
First received: August 24, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
  Purpose

The study aims to evaluate IFG, IGT or unknown type 2 diabetes mellitus in new classes at high risk to develop alterations of glucose metabolism and definition of new pathogenic mechanisms of insulin resistance and atherosclerosis.

The following classes of subjects at high risk will be considered:First degree relatives of patients with type 2 diabetes mellitus, patients with cardiovascular disease and stroke, patients with heart valve disease. age will be > 30 years, both gender.


Condition
Diabetes Mellitus, Type 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: New Physiopathogenics Mechanisms Susceptible of Pharmacological Developments (Insulin Resistance and Atherosclerosis)

Resource links provided by NLM:


Further study details as provided by IRCCS San Raffaele:

Enrollment: 1997
Study Start Date: June 1997
Study Completion Date: May 2006
Groups/Cohorts
Case: 1,2,3
  1. First degree relatives of patients with type 2 diabetes
  2. Patients with cardiovascular disease and stroke
  3. patients with heart valve disease
Control: 4
Healthy controls

Detailed Description:

The primary outcome of the study is evaluation of glucose tolerance, insulin sensitivity and insulin secretion before and 2 hours post-glucose load Secondary outcomes are evaluation of endothelial function, of natriuretic peptides and free fatty acids, and inflammation before and 2 hours post-glucose load. New candidate genes will be also evaluated.

  Eligibility

Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Fasting glucose levels <126 mg/dl
  • Age >30 years
  • Both male and female

Exclusion Criteria:

  • Type 1 diabetes
  • Known type 2 diabetes mellitus
  • Pregnancy
  • Impaired kidney and liver function
  • Previous history of malignancies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00520962

Locations
Italy
Medicine Division, Diabetology, Endocrinology and Metabolic Disease Unit, IRCCS San Raffaele
Milan, Italy, 20132
Sponsors and Collaborators
IRCCS San Raffaele
Investigators
Principal Investigator: PierMarco Piatti, MD IRCSS San Raffaele
  More Information

No publications provided by IRCCS San Raffaele

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00520962     History of Changes
Other Study ID Numbers: 199402-1369/516
Study First Received: August 24, 2007
Last Updated: August 24, 2007
Health Authority: Italy: Ministry of Health

Keywords provided by IRCCS San Raffaele:
cardiovascular disease
glucose intolerance
type 2 diabetes
endothelial dysfunction
inflammation
Age> 30 years, male and female
Fasting glucose below 126 mg/dl

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 28, 2014